An interventional study of Prebiotic and Placebo control in Muscle Loss, sponsored by University of Bath. Recruiting at 1 site in United Kingdom. Open to participants aged 65 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-16.
Sponsored by University of Bath · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Muscular Atrophy with a site in United Kingdom — 7 open to participants now, 11 under way, 2 of them phase 3. Muscular Atrophy · United Kingdom.
Among the 52 studies in Muscular Atrophy with a site in United Kingdom, this one is the 21st largest by planned enrollment of the 42 interventional ones that give a count, is the only one that started in 2024, is one of 30 with no phase, reaches primary completion later than 1 of the 10 other live ones, and was the 47th registered.
413 studies on the registry are indexed under Muscular Atrophy; 76 are open to participants now.
Browse Muscular Atrophy studies →7 of the 52 studies in Muscular Atrophy with a site in United Kingdom are open now. Recruiting first, the newest first:
MSK Doctors & Associates Ltd · Sites in United Kingdom
Ages 18+
Barts & The London NHS Trust · Sites in United Kingdom
Ages 18+
University of Nottingham · Sites in United Kingdom
Ages 18+
University of Nottingham · Sites in United Kingdom
Ages 50–90 · Men only · Healthy volunteers
University of Nottingham · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 51 Muscular Atrophy studies recruiting now, 25 (49%) set no upper age limit and 13 (25%) stop at 75 or younger; 4 take children under 18; 16 take healthy volunteers.
This study: 65 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 7
First in 2009; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 40 across 327 interventional studies indexed under Muscular Atrophy.
Median enrollment 30 across the 42 interventional studies, 29 across the 10 observational. Of the 33 that completed or were terminated, 6 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 52 have an industry lead sponsor. The 10 most frequent:
University of Bath is the lead sponsor of 94 studies on the registry; 20 are open to participants now.
University of Bath has 3 studies filed under Muscular Atrophy — fewer than ten, so there is no comparison to draw.
2 of the studies in Muscular Atrophy with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06964438University of NottinghamPostoperative Electrical Muscle Stimulation Two | 2027-02-01 |
| NCT05414292University of NottinghamImpacts of Mechanistic Target of Rapamycin (mTOR) Inhibition on Aged Human Muscle (Rapamune) | 2027-05-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 52 studies in Muscular Atrophy with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sarcopenia is a progressive muscle disease, most commonly affecting older individuals, that is categorised by 1) low muscle strength, 2) low muscle quantity or quality, and 3) low physical performance. This disease has several negative implications for human health, including an increased risk of falls, fractures, mobility limitations, and mortality. Sarcopenia also imposes significant burden on healthcare systems. For example, it was estimated that a 10% reduction in the prevalence of sarcopenia would save the US healthcare system $1.1 billion per year. Strategies to reduce the incidence and severity of sarcopenia are therefore of great interest.
One potential cause for sarcopenia is long-term, low-level inflammation, which can occur for a number of reasons. One cause may relate to the intestinal wall becoming more susceptible to leaking of toxic particles. Evidence suggests that prebiotic supplementation can reduce this 'leakage'. Galactooligosaccharide (a prebiotic) has previously been shown to reduce inflammation in elderly individuals. The investigators hypothesise that galactooligosaccharide will improve physical function in the elderly indirectly via a reduction in inflammation.
This will be a randomised, placebo-controlled, double-blind, parallel study. 32 elderly individuals (65-85 years; mix of males and females) will be randomised to one of two groups, GOS or PLACEBO. The GOS group will supplement their diet with 2.9 g galactooligosaccharide per day for 16 weeks in the form of one sachet (3.65 g) of Bimuno® Daily.
The PLACEBO group will supplement with 3.65 g maltodextrin per day for 16 weeks. The study will involve one screening visit and two main trials (baseline and 16 weeks). For the main trials, participants will complete the short physical performance battery (SPPB) and handgrip strength test. In addition, participants will provide blood, urine and faecal samples, as well as a dual-energy x-ray absorptiometry (DEXA), and a peripheral quantitative computed tomography (pQCT) scan.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Use of products marketed as prebiotics, probiotics or synbiotics within 4 weeks prior to study entry (e.g., Yakult, Actimel, Activia, VSL#3, Kefir). Regular cheese or yogurt containing lactic acid bacteria are not an exclusion criterion
At least 150 minutes of moderate-intensity activity, or 75 minutes of vigorous activity
Galactooligosaccharide (GOS) is a prebiotic supplement. Taken once daily for the duration for the intervention
Dietary Supplement: Prebiotic
Maltodextrin placebo taken once daily for the duration of the intervention
Dietary Supplement: Placebo control
Commercially available supplement (Bimuno)
maltodextrin control supplement
Mid-thigh muscle cross sectional area
pQCT assessment of mid-thigh cross sectional area
Time frame: 16 weeks
Short performance physical battery
composite test of balance, gait speed and chair stand tests where performance on each three tests scores of maximum of 4 points, combined to score a maximum of 12 points
Time frame: 16 weeks
Handgrip strength
dominant and non-dominant hand scores
Time frame: 16 weeks
appendicular lean mass/height^2 (kilograms/metres^2)
assessed via DEXA scan
Time frame: 16 weeks
gait speed
4m gait speed at usual walking pace (metres/second)
Time frame: 16 weeks
chair stand
5 time chair stand (seconds)
Time frame: 16 weeks
Plan to share: No
No publications or documents are linked to this record.
Started May 2024 (actual). Primary completion is estimated for Oct 2025, 17 months after the start.
Of 170 non-industry interventional studies with no phase under Muscular Atrophy, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 38. This study's planned 17 months is below that.
Counting every sponsor, half of 176 studies reached it within 21 months; a quarter within 9 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Prebiotics
University of Bath